<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308385">
  <stage>Registered</stage>
  <submitdate>18/08/2009</submitdate>
  <approvaldate>2/09/2009</approvaldate>
  <actrnumber>ACTRN12609000763246</actrnumber>
  <trial_identification>
    <studytitle>Protecting the lungs in patients undergoing lung transplantation.</studytitle>
    <scientifictitle>Does remote ischaemic post-conditioning reduce ischaemia reperfusion injury in patients undergoing lung transplantation?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Ischaemia-reperfusion injury in lung transplantation.</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Normal best standard practice with remote ischaemic post-conditioning using 3 cycles of transient leg ischaemia and reperfusion (5 min ischaemia followed by 5 min reperfusion, 3 times) using a thigh tourniquet at least 5 min prior to donor lung reperfusion. Total stimulus 30 minutes prior to reperfusion.</interventions>
    <comparator>Normal best standard practice.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>PaO2/FiO2 ratios as measured by arterial blood gas sampling (arterial blood analysis). Where PaO2 represents partial pressure of oxygen in arterial blood and FiO2 represents fractional of inspired oxygen.</outcome>
      <timepoint>Time 0, 6, 12, 24, 48, 72 hours.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Right ventricular myocardial performance index (transoesophageal echocardiography parameter)</outcome>
      <timepoint>After chest closure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of ECMO (extracorporeal membrane oxygenation) requirement. ie ECMO support for oxygenation or not.</outcome>
      <timepoint>During first 72 hours post-operative.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to tracheal extubation.</outcome>
      <timepoint>During hospital stay.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intensive care unit length of stay.</outcome>
      <timepoint>During hospital stay.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospital length of stay.</outcome>
      <timepoint>During hospital stay.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients listed for lung transplantation (single or double) by the Alfred Hospital lung transplant service.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients treated with sulphonylureas (oral hypoglycaemic agent).
Planned use cardiopulmonary bypass.
Planned combined heart-lung transplantation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be approached in an outpatient setting and written informed consent will be obtained. Eligible patients undergoing lung transplantation will be randomised using a computer-generated list and sealed opaque envelopes. Surgical and nursing staff will be blinded to the treatment groups as tourniquets will be applied to all patients but not inflated in controls.</concealment>
    <sequence>Randomisation will occur using a computer-generated list and sealed opaque envelopes.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/10/2009</anticipatedstartdate>
    <actualstartdate>28/12/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>27/09/2013</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>60</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>11/07/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr. Enjarn Lin</primarysponsorname>
    <primarysponsoraddress>The Alfred Hospital 
Department of anaesthesia and perioperative medicine
55 Commercial Road
Melbourne
Victoria
3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Australia New Zealnad College of Anaesthetists</fundingname>
      <fundingaddress>ANZCA House
630 St Kilda Road
Melbourne Vic 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>The Alfred Hospital Department of anaesthesia and perioperative medicine</sponsorname>
      <sponsoraddress>The Alfred Hospital 
Department of anaesthesia and perioperative medicine
55 Commercial Road
Melbourne
Victoria
3004</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof. Paul Myles</othercollaboratorname>
      <othercollaboratoraddress>The Alfred Hospital 
Department of anaesthesia and perioperative medicine
55 Commercial Road
Melbourne
Victoria
3004</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr. Silvana Marasco</othercollaboratorname>
      <othercollaboratoraddress>The Alfred Hospital 
Department of cardiothoracic surgery
55 Commercial Road
Melbourne
Victoria
3004</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Randomised controlled trial to test if short periods of lack of blood flow to the leg can improve the function of new lungs in lung transplantation.</summary>
    <trialwebsite />
    <publication>Lin, E et al. "Safety, feasibility, and effect of remote ischemic conditioning in patients undergoing lung transplantation" J Heart Lung Transplant. 2014 Nov;33(11):1139-48</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Research &amp; Ethics Unit</ethicname>
      <ethicaddress>55 Commercial Road
PO Box 315 Prahran
Victoria 3181 Australia</ethicaddress>
      <ethicapprovaldate>22/12/2009</ethicapprovaldate>
      <hrec>1/09/0257</hrec>
      <ethicsubmitdate>27/08/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Enjarn Lin</name>
      <address>The Alfred Hospital 
Department of anaesthesia and perioperative medicine
55 Commercial Road
Melbourne
Victoria
3004</address>
      <phone>+613 90763176</phone>
      <fax />
      <email>e.lin@alfred.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Enjarn Lin</name>
      <address>The Alfred Hospital 
Department of anaesthesia and perioperative medicine
55 Commercial Road
Melbourne
Victoria
3004</address>
      <phone>+613 90763176</phone>
      <fax />
      <email>e.lin@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Enjarn Lin</name>
      <address>The Alfred Hospital 
Department of anaesthesia and perioperative medicine
55 Commercial Road
Melbourne
Victoria
3004</address>
      <phone>+613 90763176</phone>
      <fax />
      <email>e.lin@alfred.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>